Since radiorecurrent prostate cancer usually appears as a focal in-field recurrence [9,10,11,12], a higher PPV is expected for combined imaging with PSMA PET/CT and mp-MRI in patients with increasing PSA-values after primary radiotherapy compared to the primary pretreatment setting. Here, FOLH1 is linked to prostate carcinoma.